New cocktail targets genetic weakness in advanced breast cancer
NCT ID NCT07618390
First seen Jun 02, 2026 · Last updated Jun 23, 2026 · Updated 6 times
Summary
This phase 2 trial tests a combination of three drugs—inavolisib, ribociclib, and fulvestrant—in 160 Chinese women with a specific form of advanced breast cancer (PIK3CA-mutant, HR+, HER2-). The goal is to see if the combo can delay cancer growth. Participants will take daily pills and receive injections until their disease worsens or side effects become too severe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
inavolisib, ribociclib, and fulvestrant
What this could lead to
If successful, this combination could offer a new first-line treatment option for Chinese patients with a specific genetic subtype of advanced breast cancer.
What could go wrong
This is an early-phase, single-arm study with no placebo group, so results may not be definitive. Side effects from the three-drug combination could be significant.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.